← Back to Patent Explorer
US4357343A Expired / Lapsed US ⏱️ 0.0 years remaining

Nutritional composition for management of renal failure

Assignee: Baxter International Inc
•
Filing: 1981-06-26
•
Granted: 1982-11-02
•
Expires: 2001-06-26
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A novel amino acid composition is provided for the nutritional maintenance of renal failure patients.

Inventors

  • 👤 David C. Madsen
  • 👤 Hugh N. Tucker

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-29 08:32
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/01

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 95 words
A composition for treating renal failure or deficiency, comprising an amino acid mixture consisting of the following amino acids in the stated proportions: ______________________________________ Mole Percent Range Amino Acid about from ______________________________________ L-Leucine 8.6 to 8.9 L-Phenylalanine 5.6 to 5.8 L-Methionine 7.2 to 6.5 L-Lysine (free base) 5.8 to 6.0 L-Isoleucine 7.2 to 7.5 L-Valine 12.1 to 13.6 L-Histidine 5.2 to 6.9 L-Threonine 5.9 to 6.3 L-Tryptophan 1.4 to 1.5 L-Alanine 11.7 to 12.4 Glycine 7.7 to 8.9 L-Arginine 5.6 to 7.0 L-Proline 5.9 to 6.2 L-Tyrosine 0.3 to 0.6 L-Serine 5.5 to 6.3 ______________________________________
Claim 2
Dependent Claim 95 words
A composition for treating renal failure or deficiency, comprising an amino acid mixture consisting of the following amino acids in the stated proportions: ______________________________________ Mole Percent Range Amino Acid about from ______________________________________ L-Leucine 8.6 to 8.9 L-Phenylalanine 5.6 to 5.8 L-Methionine 7.2 to 6.5 L-Lysine (free base) 5.8 to 6.0 L-Isoleucine 7.2 to 7.5 L-Valine 12.1 to 13.6 L-Histidine 5.2 to 6.9 L-Threonine 5.9 to 6.3 L-Tryptophan 1.4 to 1.5 L-Alanine 11.7 to 12.4 Glycine 7.7 to 8.9 L-Arginine 5.6 to 7.0 L-Proline 5.9 to 6.2 L-Tyrosine 0.3 to 0.6 L-Serine 5.5 to 6.3 ______________________________________
Claim 3
Dependent Claim 59 words
The composition of claim 1 wherein the mole percentages of L-leucine, L-phenylalanine, L-methionine, L-lysine, L-isoleucine, L-valine, L-histidine, L-threonine, L-tryptophan, L-alanine, glycine L-arginine, L-proline, L-tyrosine, and L-serine are, respectively, about 8.6, about 5.7, about 7.2, about 5.8, about 7.2, about 12.1, about 6.9, about 5.9, about 1.5, about 11.7, about 8.9, about 5.6, about 6.1, about 0.5 and about 6.3.
Claim 4
Dependent Claim 16 words
The composition of claim 2 further comprising water soluble vitamins and digestively assimilable carbohydrates and fats.
Claim 5
Dependent Claim 21 words
The composition of claim 2 in aqueous solution in a concentration of about from 1 to 10 grams of amino acid/dl.
Claim 6
Dependent Claim 14 words
The composition of claim 2 which is essentially free of electrolytes and fat-soluble vitamins.
Claim 7
Independent Claim 23 words
A method for treating a renal failure patient, comprising orally administering the composition of claims 2, 3, 4 or 5 to said patient.
Claim 8
Dependent Claim 59 words
The composition of claim 1 wherein the mole percentages of L-leucine, L-phenylalanine, L-methionine, L-lysine, L-isoleucine, L-valine, L-histidine, L-threonine, L-tryptophan, L-alanine, glycine L-arginine, L-proline, L-tyrosine, and L-serine are, respectively, about 8.9, about 5.6, about 7.4, about 6.0, about 7.5, about 12.4, about 5.2, about 6.3, about 1.4, about 12.4, about 7.7, about 7.0, about 6.1, about 0.5 and about 5.5.
Claim 9
Dependent Claim 23 words
The composition of claim 7 as a sterile aqueous solution at a concentration of about from 3 to 10 grams of amino acid/dl.
Claim 10
Dependent Claim 11 words
The composition of claim 7 which is essentially free of electrolytes.
Claim 11
Dependent Claim 11 words
The composition of claim 8 wherein the pH is about 6.0.
Claim 12
Dependent Claim 23 words
A method for treating a renal failure patient, comprising parenteral administration of the composition of claim 8, 9 or 10 to said patient.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1985-11-01 1986-05-03 1986-11-02 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1989-11-01 1990-05-03 1990-11-02 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1993-11-01 1994-05-03 1994-11-02 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag